Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis
Purpose: Immunomodulatory agents, including conventional immunosuppressive treatment and biologics, are the mainstay of treating chronic uveitis. Janus kinase ( JAK) inhibitors, one of the newest biologics, have shown successful outcomes in treating autoimmune diseases such as rheumatoid arthritis...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Knowledge E
2025-05-01
|
| Series: | Journal of Ophthalmic & Vision Research |
| Subjects: | |
| Online Access: | https://knepublishing.com/index.php/JOVR/article/view/14952 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849322073683394560 |
|---|---|
| author | Diego Dominguez Sawyer Vaclaw Cynthia McClard Matlock A. Jeffries Jila Noori |
| author_facet | Diego Dominguez Sawyer Vaclaw Cynthia McClard Matlock A. Jeffries Jila Noori |
| author_sort | Diego Dominguez |
| collection | DOAJ |
| description |
Purpose: Immunomodulatory agents, including conventional immunosuppressive treatment and biologics, are the mainstay of treating chronic uveitis. Janus kinase ( JAK) inhibitors, one of the newest biologics, have shown successful outcomes in treating autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases by suppressing the JAK/signal transducers and transcription (STAT) pathway. We present two cases of recalcitrant chronic uveitis with significant improvement in intraocular inflammation by using upadacitinib, a selective JAK1 inhibitor.
Case Reports: The first case is a 59-year-old female with HLA-B27-positive Chron’s disease and chronic anterior and intermediate uveitis who experienced an improvement in visual acuity, anterior chamber and vitreous inflammation, and cystoid macular edema on upadacitinib. The second patient is a 71-year-old female with birdshot chorioretinopathy, intolerant of initially used systemic immunosuppressive agents who showed significant improvement in vitreous inflammation, retinal phlebitis, and choroiditis after treatment with upadacitinib.
Conclusion: Utilizing JAK inhibitors such as upadacitinib in treating uveitis, whether in isolated forms or in the context of systemic autoimmune diseases, may require further evaluation by controlled cohort studies.
|
| format | Article |
| id | doaj-art-a1e58214a5a14f7c8fb6cb002f4d8922 |
| institution | Kabale University |
| issn | 2008-2010 2008-322X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Knowledge E |
| record_format | Article |
| series | Journal of Ophthalmic & Vision Research |
| spelling | doaj-art-a1e58214a5a14f7c8fb6cb002f4d89222025-08-20T03:49:32ZengKnowledge EJournal of Ophthalmic & Vision Research2008-20102008-322X2025-05-012010.18502/jovr.v20.14952Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic UveitisDiego Dominguez0Sawyer Vaclaw1Cynthia McClard 2Matlock A. Jeffries3Jila Noori4Oklahoma State University College of Osteopathic Medicine, Tulsa, OKUniversity of Oklahoma College of Medicine, Oklahoma City, OK, Cincinnati Eye Institute, Cincinnati, OHUniversity of Oklahoma College of Medicine, Oklahoma City, OKUniversity of Oklahoma College of Medicine, Oklahoma City, OK Purpose: Immunomodulatory agents, including conventional immunosuppressive treatment and biologics, are the mainstay of treating chronic uveitis. Janus kinase ( JAK) inhibitors, one of the newest biologics, have shown successful outcomes in treating autoimmune diseases such as rheumatoid arthritis and inflammatory bowel diseases by suppressing the JAK/signal transducers and transcription (STAT) pathway. We present two cases of recalcitrant chronic uveitis with significant improvement in intraocular inflammation by using upadacitinib, a selective JAK1 inhibitor. Case Reports: The first case is a 59-year-old female with HLA-B27-positive Chron’s disease and chronic anterior and intermediate uveitis who experienced an improvement in visual acuity, anterior chamber and vitreous inflammation, and cystoid macular edema on upadacitinib. The second patient is a 71-year-old female with birdshot chorioretinopathy, intolerant of initially used systemic immunosuppressive agents who showed significant improvement in vitreous inflammation, retinal phlebitis, and choroiditis after treatment with upadacitinib. Conclusion: Utilizing JAK inhibitors such as upadacitinib in treating uveitis, whether in isolated forms or in the context of systemic autoimmune diseases, may require further evaluation by controlled cohort studies. https://knepublishing.com/index.php/JOVR/article/view/14952Birdshot ChorioretinopathyJAK InhibitorsUpadacitinibUveitis |
| spellingShingle | Diego Dominguez Sawyer Vaclaw Cynthia McClard Matlock A. Jeffries Jila Noori Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis Journal of Ophthalmic & Vision Research Birdshot Chorioretinopathy JAK Inhibitors Upadacitinib Uveitis |
| title | Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis |
| title_full | Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis |
| title_fullStr | Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis |
| title_full_unstemmed | Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis |
| title_short | Successful Use of Upadacitinib, a Selective JAK Inhibitor, in the Treatment of Two Cases of Recalcitrant Chronic Uveitis |
| title_sort | successful use of upadacitinib a selective jak inhibitor in the treatment of two cases of recalcitrant chronic uveitis |
| topic | Birdshot Chorioretinopathy JAK Inhibitors Upadacitinib Uveitis |
| url | https://knepublishing.com/index.php/JOVR/article/view/14952 |
| work_keys_str_mv | AT diegodominguez successfuluseofupadacitinibaselectivejakinhibitorinthetreatmentoftwocasesofrecalcitrantchronicuveitis AT sawyervaclaw successfuluseofupadacitinibaselectivejakinhibitorinthetreatmentoftwocasesofrecalcitrantchronicuveitis AT cynthiamcclard successfuluseofupadacitinibaselectivejakinhibitorinthetreatmentoftwocasesofrecalcitrantchronicuveitis AT matlockajeffries successfuluseofupadacitinibaselectivejakinhibitorinthetreatmentoftwocasesofrecalcitrantchronicuveitis AT jilanoori successfuluseofupadacitinibaselectivejakinhibitorinthetreatmentoftwocasesofrecalcitrantchronicuveitis |